BioSenic Puts Fracture Cell Therapy Program on Hold After Mid-Stage Failure

Belgium-based biotech company BioSenic has announced that it is suspending the development of its investigational allogeneic cell therapy derived from mesenchymal stem cells, called ALLOB, which was being assessed as a treatment for tibial fractures. The decision to pause ALLOB’s development comes after disappointing results in a Phase IIb trial, which had been designed to evaluate the candidate..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms

Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide

Merck's efinopegdutide has received FDA Fast Track designation for the treatment of non-alcoholic steatohepatitis (NASH), and Merck has released Phase IIa study results comparing efinopegdutide to Novo Nordisk's semaglutide. The new NAFLD data will be presented at the upcoming European Association for the Study of the Liver annual congress, and Merck plans to use both this data and the Fast Trac..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms